Labcorp Holdings Inc. and Children’s Hospital of Philadelphia (CHOP) announced a partnership to accelerate the discovery, development and nationwide availability of specialized pediatric diagnostics. The collaboration will create a joint innovation pipeline focused on oncology, metabolic disease and autoimmune conditions, with the goal of delivering breakthrough tests to children across the country more quickly and at greater scale.
Labcorp’s Q4 2025 earnings provide context for the partnership. The company reported earnings per share of $4.07, beating the consensus estimate of $3.95 by $0.12, while revenue of $3.52 billion fell short of the $3.56 billion expected. The EPS beat was driven by continued strength in the Diagnostics and Central Laboratory businesses, as well as disciplined cost management. The revenue miss reflected weaker demand in some segments, but overall growth remained robust. Management guided 2026 revenue growth to 5.4% and adjusted EPS growth to about 9%, signaling confidence in the company’s trajectory.
Segment data show the Diagnostics division grew 6% in revenue, with over 4% organic gains, driven by oncology, women’s health and neurology testing. Labcorp already offers a range of pediatric services, including genetic testing for developmental issues and rare diseases. The partnership expands these offerings by leveraging CHOP’s Center for Diagnostic Innovation, which is a hub for pioneering diagnostic development.
"Our shared aim to improve children’s health makes this collaboration so powerful," said Stephen R. Master, M.D., Ph.D., division chief and director of metabolic and advanced diagnostics at CHOP. "By pairing CHOP’s pediatric leadership with Labcorp’s nationwide reach, we seek to deliver important new and specialized tests to children and their families more efficiently and at greater scale." "By combining CHOP’s deep pediatric expertise with Labcorp’s scientific capabilities and national reach, we can bring pediatric diagnostic innovations to patients faster and make advanced testing accessible to many more families," added Bryan Vaughn, executive vice president, Diagnostics at Labcorp. "Today's announcement marks an important milestone at the intersection of scientific research and collaboration," said Joseph Mitchell, M.D., president at CHOP. "Our commitment to innovation has always been driven by one goal: improving the lives of children."
Labcorp’s chairman and CEO Adam Schechter noted that in 2025 the company grew revenue over 7% and delivered double‑digit adjusted EPS growth, margin expansion and strong free cash flow, driven by continued strength in its Diagnostics and Central Laboratory businesses. The partnership positions Labcorp to expand its specialty testing portfolio into the pediatric market, strengthen its role as a national laboratory partner for health systems, and accelerate the delivery of advanced diagnostics to children nationwide.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.